Soltamox (Tamoxifen Citrate) for Breast Cancer

Overview
Soltamox is approved by the U.S. Food and Drug Administration (FDA) for the treatment of estrogen receptor (ER)-positive metastatic breast cancer, as an adjuvant treatment for early-stage ER-positive breast cancer, to reduce the risk of invasive breast cancer following breast surgery and radiation in adults with ductal carcinoma in situ (DCIS), and to reduce the incidence of breast cancer in adults at high risk. Soltamox is also known by its drug name, tamoxifen citrate.

Soltamox is a selective estrogen receptor modulator (SERM). It works by binding to estrogen receptors on cancer cells, which blocks estrogen from binding and thereby slows or stops the growth of the cancer cells.

How do I take it?
Prescribing information states that Soltamox is taken orally as a solution, once or twice per day, depending on dosage size. Dosage size varies from person to person depending on their diagnosis. The drug should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Soltamox include hot flashes, mood disturbances, vaginal discharge, vaginal bleeding, nausea, and fluid retention.

Rare but serious side effects may include uterine malignancies (cancers), thromboembolic events (blood clots), embryo-fetal toxicity (harm to an unborn baby), and liver abnormalities, some of which can be fatal.

For more information about this treatment, visit:

Label: Soltamox — Tamoxifen Citrate Liquid — DailyMed

Soltamox — Drugs.com